Healthy Living

Developments in New Lupus Immunotherapy

Developments in New Lupus Immunotherapy

The results from a study on dendritic cells or DCs as targets for treatment shows promise in the area of immunotherapy for patients who suffer from SLE (systemic lupus erythematosus).

A study published in Immunology showed that DCs that originated from monocytes taken from both SLE patients and donors who were in good health, and then treated with RGZ and DEXA, exemplified immunosuppressive qualities. This can be quite a game-changer for treatment considering that this discovery can lead to ways of redirecting the body’s immune response to where relief—and even longevity—can become a possible reality.